Technology assessment and cost-effectiveness analysis: misguided guidelines?
作者信息
Naylor C D, Williams J I, Basinski A, Goel V
机构信息
Department of Medicine, University of Toronto, Ont.
出版信息
CMAJ. 1993 Mar 15;148(6):921-4.
Abstract
摘要
相似文献
1
Technology assessment and cost-effectiveness analysis: misguided guidelines?技术评估与成本效益分析：误导性指南？
CMAJ. 1993 Mar 15;148(6):921-4.
2
3
Tentative guidelines for using clinical and economic evaluations revisited.再探临床与经济评估使用的暂行指南。
CMAJ. 1993 Mar 15;148(6):927-9.
4
On being NICE in the UK: guidelines for technology appraisal for the NHS in England and Wales.英国的“国民健康与临床优化研究所”（NICE）：英格兰和威尔士国民医疗服务体系（NHS）技术评估指南
Health Econ. 2002 Apr;11(3):185-91. doi: 10.1002/hec.706.
5
6
The importance of subjective values to medical technology assessment and health policy.主观价值对医学技术评估和卫生政策的重要性。
J Invasive Cardiol. 1993 Jan-Feb;5(1):17-22.
7
Reflections on science, judgment, and value in evidence-based decision making: a conversation with David Eddy by Sean R. Tunis.循证决策中的科学、判断与价值之思考：肖恩·R·图尼斯与大卫·埃迪的对话
Health Aff (Millwood). 2007 Jul-Aug;26(4):w500-15. doi: 10.1377/hlthaff.26.4.w500. Epub 2007 Jun 19.
8
Medical necessity: trying to reach consensus.
Hosp Technol Ser. 1996 May;15(6):5, 10.
9
The limited regulatory potential of medical technology assessment.医学技术评估有限的监管潜力。
Va Law Rev. 1996 Nov;82(8):1525-1622.
10
Does assessment of medical practices have a future?对医疗实践的评估有未来吗？
Va Law Rev. 1996 Nov;82(8):1623-40.
引用本文的文献
1
Ontario's formulary committee: how recommendations are made.安大略省药品目录委员会：建议是如何制定的。
Pharmacoeconomics. 2003;21(4):285-94. doi: 10.2165/00019053-200321040-00006.
2
The emerging government requirement for economic evaluation of pharmaceuticals.政府对药品经济评估的新要求。
Pharmacoeconomics. 1994;6 Suppl 1:42-50. doi: 10.2165/00019053-199400061-00012.
3
Multi-attribute preference functions. Health Utilities Index.多属性偏好函数。健康效用指数。
Pharmacoeconomics. 1995 Jun;7(6):503-20. doi: 10.2165/00019053-199507060-00005.
4
Costs and cost-effectiveness of a universal, school-based hepatitis B vaccination program.一项普及的、基于学校的乙肝疫苗接种计划的成本及成本效益
Am J Public Health. 1998 Nov;88(11):1638-44. doi: 10.2105/ajph.88.11.1638.
5
Interpretation of cost-effectiveness analyses.成本效益分析的解读
J Gen Intern Med. 1998 Oct;13(10):716-7. doi: 10.1046/j.1525-1497.1998.00211.x.
6
Guidelines for writing guidelines.撰写指南的指南。
CMAJ. 1994 Sep 1;151(5):507-8.
7
Technology assessment of anaesthesia monitors: problems and future directions.
Can J Anaesth. 1995 Mar;42(3):234-9. doi: 10.1007/BF03010685.
8
Postoperative pain management--back to basics.术后疼痛管理——回归基础
Can J Anaesth. 1995 Jun;42(6):453-7. doi: 10.1007/BF03011679.
本文引用的文献
1
Applications of cost-benefit analysis to health care. Departures from welfare economic theory.成本效益分析在医疗保健中的应用。与福利经济理论的背离。
J Health Econ. 1987 Sep;6(3):211-25. doi: 10.1016/0167-6296(87)90009-9.
2
Economic analysis and clinical trials.经济分析与临床试验。
Control Clin Trials. 1984 Jun;5(2):115-28. doi: 10.1016/0197-2456(84)90118-1.
3
Rules of evidence and clinical recommendations on the use of antithrombotic agents.抗血栓药物使用的证据规则和临床建议。
Chest. 1989 Feb;95(2 Suppl):2S-4S.
4
Where to draw the line against cholesterol.胆固醇的界限在哪里。
Ann Intern Med. 1989 Oct 15;111(8):625-7. doi: 10.7326/0003-4819-111-8-625.
5
Quality-adjusted life-years. Ethical implications for physicians and policymakers.质量调整生命年。对医生和政策制定者的伦理影响。
JAMA. 1990 Jun 6;263(21):2917-21. doi: 10.1001/jama.263.21.2917.
6
Health care technology assessment: linking science and policy-making.医疗技术评估：连接科学与决策制定。
CMAJ. 1992 Feb 15;146(4):461-2.
7
Potential cost effectiveness of intravenous tissue plasminogen activator versus streptokinase for acute myocardial infarction.
Can J Cardiol. 1992 Jan-Feb;8(1):31-8.
8
Incorporating variations in the quality of individual randomized trials into meta-analysis.将个体随机试验质量的差异纳入荟萃分析。
J Clin Epidemiol. 1992 Mar;45(3):255-65. doi: 10.1016/0895-4356(92)90085-2.
Zotero 插件